Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®
08:00am, Thursday, 03'rd Oct 2024
Four new targets nominated for total of six nominated targets, including FcRn (VYVGART® Hytrulo), for ENHANZE® drug delivery technology Halozyme to receive total upfront payment of $30 million for e
OCREVUS ZUNOVO™ has the potential to expand treatment options to centers without IV infrastructure or with IV constraints SAN DIEGO , Sept. 13, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NAS
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
08:00pm, Thursday, 12'th Sep 2024
FDA approval marks first and only subcutaneous anti-PD-(L)1 cancer immunotherapy SAN DIEGO , Sept. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that
Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 05'th Sep 2024
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 02'nd Sep 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme to Present at Upcoming Investor Conferences
08:30am, Wednesday, 28'th Aug 2024
SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Inve
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
10:41am, Tuesday, 27'th Aug 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Final Trade: LULU, VIK, HALO, CCJ
06:33pm, Friday, 23'rd Aug 2024
The final trades of the day with CNBC's Leslie Picker and the Fast Money traders.
Halozyme Earnings, Guidance Point to Bullish Future
03:03pm, Friday, 23'rd Aug 2024
Strong revenue growth and a bright outlook have Halozyme Therapeutics, Inc. (HALO) shares rising.
Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals
02:58am, Wednesday, 14'th Aug 2024
Based on fundamental analysis, Halozyme Therapeutics, Inc. presents high returns on invested capital and returns on equity which will drive returns for investors. HALO is trading at a significant disc
Stock Market Fades Badly As Dow Jones Index Turns Back At This Critical Level
05:41pm, Wednesday, 07'th Aug 2024
The stock market's bearish reversal left its rebound in doubt but a rally attempt remains in play.
Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up
11:41am, Wednesday, 07'th Aug 2024
Halozyme (HALO) reports better-than-expected second-quarter 2024 results. The company maintains revenue guidance for 2024.
Halozyme Therapeutics, Inc. (HALO) Q2 2024 Earnings Call Transcript
11:44pm, Tuesday, 06'th Aug 2024
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Tram Bui - Vice President of Investor Relations and Corporate Communications
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
07:36pm, Tuesday, 06'th Aug 2024
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates
06:51pm, Tuesday, 06'th Aug 2024
Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.74 per share a year ago.
